Europe Branded Generics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-Inflammatory, and Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies, and Drug Stores), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Antihypertensive, Lipid-Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptic, and Others), and Formulation Type (Oral, Parenteral, Topical, and Others)
The branded generics market in Europe is expected to grow from US$ 45.81 billion in 2022 to US$ 81.30 billion by 2028; it is estimated to grow at a CAGR of 10.0% from 2022 to 2028.
Players in the pharmaceutical industry are adopting various strategies, including product differentiation, to reduce development costs and maximize profits. Product differentiation involves developing innovative products based on an existing product by enhancing its features, performance, and efficacy. Product differentiation paves the way for strengthening product pipeline and lifecycle management. As generic drugs contain the same active pharmaceutical ingredients as the brand-name products, differentiation in color, shape, taste, inactive ingredients, preservatives, and packaging result in high demand for branded generics. Therefore, differentiation in the final product is expected to offer lucrative growth opportunities for the competitive players in the market in the coming years.
Additionally, prominent players operating the market are offering low-cost branded generics to remain competitive in the market. For instance, in July 2020, Takeda Pharmaceutical Company announced a joint venture with Teva Pharmaceuticals Industries Ltd. to commercialize complex generics products, specialty assets, and other pipeline generic medicines. Further, key players in the branded generics segment offer low-cost branded generics to remain competitive in the Europe market. This can be achieved by strategically sourcing raw materials from emerging economies and partnering with suppliers. All these factors would provide lucrative opportunities for the overall branded generics market growth during the forecast period.
By introducing new features and technologies, vendors in the Europe branded generics market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market at a good CAGR during the forecast period.
Europe Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)
Europe Branded Generics Market Segmentation
Europe branded generics market is segmented into therapeutic application, distribution channel, drug class, formulation type and country. The therapeutic application segment of the Europe branded generics market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, and analgesics and anti-inflammatory. In 2022, the others segment held the largest share of the market, by therapeutic application. The Europe branded generics market, by distribution channel is hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment is likely to hold the largest share of the market in 2022. The Europe branded generics market, by drug class is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment is likely to hold the largest share of the market in 2022. The Europe branded generics market, based on formulation type is segmented into oral, parenteral, topical, and other. In 2022, the oral segment held the largest share of the market, by formulation type. Based on country, the Europe branded generics market is segmented into France, Germany, Italy, UK, Spain, and the Rest of Europe. The Rest of Europe held the largest market share in 2022.
Aspen Holdings, AstraZeneca, Bausch Health (Valeant Pharmaceuticals), Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Hetero, Lupin, Mylan N.V., Par Pharmaceuticals, Sandoz International Gmbh, Sanofi, and Teva Pharmaceutical Industries Ltd. are among the leading companies in the branded generics market operating in this region.
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Branded Generics Market – By Therapeutic Application
1.3.2 Europe Branded Generics Market – By Distribution Channel
1.3.3 Europe Branded Generics Market – By Drug Class
1.3.4 Europe Branded Generics Market – By Formulation Type
1.3.5 Europe Branded Generics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Branded Generics Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Branded Generics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Popularity of Branded Generics
5.1.2 Rise in Government Initiatives for Promoting Branded Generics
5.2 Market Restraints
5.2.1 Switching Brands, Poorer Clinical Outcomes and Adverse Effects of Generic Medications
5.3 Market Opportunities
5.3.1 New Opportunities Owing to Product Differentiation
5.4 Future Trends
5.4.1 More Focus Upon Utility of Branded Generics by Healthcare Providers and Professionals
5.5 Impact Analysis
6. Branded Generics Market– Europe Analysis
6.1 Europe Branded Generics Market Revenue Forecast and Analysis
6.2 Europe Branded Generics Market, By Country - Forecast and Analysis
7. Europe Branded Generics Market Revenue and Forecast To 2028– by Therapeutic Application
7.1 Overview
7.2 Europe Branded Generics Market Revenue Share, By Therapeutic Application: Market Revenue and Forecast Analysis (US$ Billion)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology Market Revenue and Forecast to 2028 (US$ Billion)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.5 Diabetes
7.5.1 Overview
7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
7.6 Neurology
7.6.1 Overview
7.6.2 Neurology Market Revenue and Forecast to 2028 (US$ Billion)
7.7 Gastrointestinal Diseases
7.7.1 Overview
7.7.2 Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.8 Dermatology Diseases
7.8.1 Overview
7.8.2 Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
7.9 Analgesics and Anti-Inflammatory
7.9.1 Overview
7.9.2 Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
7.10 Others
7.10.1 Overview
7.10.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
8. Europe Branded Generics Market Analysis and Forecast to 2028 by Distribution Channel
8.1 Europe Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
8.2 Hospital Pharmacies
8.2.1 Overview
8.2.2 Hospital Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.3 Retail Pharmacies
8.3.1 Overview
8.3.2 Retail Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.4 Online Pharmacies
8.4.1 Overview
8.4.2 Online Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
8.5 Drug Stores
8.5.1 Overview
8.5.2 Drug Stores: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9. Europe Branded Generics Market Analysis and Forecast to 2028 by Drug Class
9.1 Europe Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
9.2 Alkylating Agents
9.2.1 Overview
9.2.2 Alkylating Agents: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.3 Antimetabolites
9.3.1 Overview
9.3.2 Antimetabolites: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.4 Hormones
9.4.1 Overview
9.4.2 Hormones: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.5 Anti-hypertensive
9.5.1 Overview
9.5.2 Anti-hypertensive: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.6 Lipid Lowering Drugs
9.6.1 Overview
9.6.2 Lipid Lowering Drugs: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.7 Anti-Depressants
9.7.1 Overview
9.7.2 Anti-Depressants: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.8 Anti-psychotics
9.8.1 Overview
9.8.2 Anti-psychotics: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.9 Anti-epileptic
9.9.1 Overview
9.9.2 Anti-epileptic: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
9.10 Others
9.10.1 Overview
9.10.2 Others: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
10. Europe Branded Generics Market Analysis and Forecast to 2028 – by Formulation Type
10.1 Overview
10.2 Europe Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Billion)
10.4 Parenteral
10.4.1 Overview
10.4.2 Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
10.5 Topical
10.5.1 Overview
10.5.2 Topical Market Revenue and Forecast to 2028 (US$ Billion)
10.6 Others
10.6.1 Overview
10.6.2 Others Market Revenue and Forecast to 2028 (US$ Billion)
11. Europe Branded Generics Market Revenue and Forecasts to 2028 Country Analysis
11.1 Overview
11.1.1 Europe: Branded Generics Market, by Country, 2022 & 2028 (%)
11.1.1.1 Germany: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.1 Germany: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.2 Germany: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.3 Germany: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.4 Germany: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.1.5 Germany: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2 France: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.1 France: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.2 France: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.3 France: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.4 France: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.2.5 France: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3 UK: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.1 UK: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.2 UK: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.3 UK: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.4 UK: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.3.5 UK: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4 Italy: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.1 Italy: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.2 Italy: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.3 Italy: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.4 Italy: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.4.5 Italy: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5 Spain: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5.1 Spain: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5.2 Spain: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5.3 Spain: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5.4 Spain: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.5.5 Spain: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6 Rest of Europe: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.1 Rest of Europe: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.2 Rest of Europe: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.3 Rest of Europe: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.4 Rest of Europe: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
11.1.1.6.5 Rest of Europe: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
12. Branded Generics Market–Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 MYLAN N.V.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bausch Health Companies Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Lupin
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Sanofi
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 ASTRAZENECA PLC.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Par Pharmaceuticals, INC
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Sandoz International GMBH
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Aspen Holdings
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 Hetero
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
Table 2. Germany: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
Table 3. Germany: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 4. Germany: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
Table 5. France: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
Table 6. France: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
Table 7. France: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 8. France: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
Table 9. UK: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
Table 10. UK: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
Table 11. UK: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 12. UK: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
Table 13. Italy: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
Table 14. Italy: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
Table 15. Italy: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 16. Italy: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
Table 17. Spain: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
Table 18. Spain: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
Table 19. Spain: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 20. Spain: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
Table 21. Rest of Europe: Branded Generics Market, by Therapeutic Application – Revenue and Forecast to 2028 (US$ Billion)
Table 22. Rest of Europe: Branded Generics Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Billion)
Table 23. Rest of Europe: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)
Table 24. Rest of Europe: Branded Generics Market, by Formulation Type – Revenue and Forecast to 2028 (US$ Billion)
Table 25. Organic Developments Done By Companies
Table 26. Inorganic Developments Done By Companies
Table 27. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Branded Generics Market Segmentation
Figure 2. Europe Branded Generics Market, By Country
Figure 3. Europe Branded Generics Market Overview
Figure 4. Others Segment Held Largest Share of Drug Class Segment in Europe Branded Generics Market
Figure 5. UK is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis of Drivers and Restraints on Europe Branded Generics Market
Figure 9. Europe Branded Generics Market – By Country Forecast and Analysis – 2019 - 2028
Figure 10. Europe Branded Generics Market Revenue Share, By Therapeutic Application: Market Analysis and Forecast 2022 and 2028 (%)
Figure 11. Europe Oncology Market Revenue and Forecast to 2028 (US$ Billion)
Figure 12. Europe Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)
Figure 13. Europe Diabetes Market Revenue and Forecast to 2028 (US$ Billion)
Figure 14. Europe Neurology Market Revenue and Forecast to 2028 (US$ Billion)
Figure 15. Europe Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)
Figure 16. Europe Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)
Figure 17. Europe Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)
Figure 18. Europe Others Market Revenue and Forecast to 2028 (US$ Billion)
Figure 19. Europe Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)
Figure 20. Europe Hospital Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 21. Europe Retail Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 22. Europe Online Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 23. Europe Drug Stores: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 24. Europe Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)
Figure 25. Europe Alkylating Agents: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 26. Europe Antimetabolites: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 27. Europe Hormones: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 28. Europe Anti-hypertensive: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 29. Europe Lipid Lowering Drugs: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 30. Europe Anti-Depressants: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 31. Europe Anti-psychotics: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 32. Europe Anti-epileptic: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 33. Europe Others: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 34. Europe Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)
Figure 35. Europe Oral Market Revenue and Forecast to 2028 (US$ Billion)
Figure 36. Europe Parenteral Market Revenue and Forecast to 2028 (US$ Billion)
Figure 37. Europe Topical Market Revenue and Forecast to 2028 (US$ Billion)
Figure 38. Europe Others Market Revenue and Forecast to 2028 (US$ Billion)
Figure 39. Europe: Branded Generics Market, by Key Country – Revenue (2022) (US$ Billion)
Figure 40. Europe: Branded Generics Market, by Country, 2022 & 2028 (%)
Figure 41. Germany: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 42. France: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 43. UK: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 44. Italy: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 45. Spain: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 46. Rest of Europe: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)
Figure 47. Growth Strategies Done by the Companies in the Market (%)
- Aspen Holdings
- AstraZeneca
- Bausch Health (Valeant Pharmaceuticals)
- Dr. Reddy's Laboratories Inc.
- GlaxoSmithKline plc
- Hetero
- Lupin
- MYLAN N.V.
- Par Pharmaceuticals
- Sandoz International Gmbh
- Sanofi
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe branded generics market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe branded generics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the branded generics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution